Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis

por Xie, Rujia, Deng, Chenhui, Wang, Qiang, Kanik, Keith S., Nicholas, Timothy, Menon, Sujatha
Publicado 2019

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

por Strand, Vibeke, Kremer, Joel, Wallenstein, Gene, Kanik, Keith S., Connell, Carol, Gruben, David, Zwillich, Samuel H., Fleischmann, Roy
Publicado 2015

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial

por Østergaard, Mikkel, Wu, Joseph, Fallon, Lara, Sherlock, Sarah P., Wang, Cunshan, Fleishaker, Dona, Kanik, Keith S., Maksymowych, Walter P.
Publicado 2023

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

por van der Heijde, Désirée, Deodhar, Atul, Wei, James C, Drescher, Edit, Fleishaker, Dona, Hendrikx, Thijs, Li, David, Menon, Sujatha, Kanik, Keith S
Publicado 2017

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients

por Maksymowych, Walter P, van der Heijde, Désirée, Baraliakos, Xenofon, Deodhar, Atul, Sherlock, Sarah P, Li, David, Fleishaker, Dona, Hendrikx, Thijs, Kanik, Keith S
Publicado 2018

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

por Fleischmann, Roy, Kremer, Joel, Tanaka, Yoshiya, Gruben, David, Kanik, Keith, Koncz, Tamas, Krishnaswami, Sriram, Wallenstein, Gene, Wilkinson, Bethanie, Zwillich, Samuel H., Keystone, Edward
Publicado 2016

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

por Helliwell, Philip, Coates, Laura C., FitzGerald, Oliver, Nash, Peter, Soriano, Enrique R., Elaine Husni, M., Hsu, Ming-Ann, Kanik, Keith S., Hendrikx, Thijs, Wu, Joseph, Kudlacz, Elizabeth
Publicado 2018

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

por Nash, Peter, Coates, Laura C., Fleischmann, Roy, Papp, Kim A., Gomez-Reino, Juan Jesus, Kanik, Keith S., Wang, Cunshan, Wu, Joseph, Menon, Sujatha, Hendrikx, Thijs, Ports, William C.
Publicado 2018

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

por Veale, Douglas J, McGonagle, Dennis, McInnes, Iain B, Krueger, James G, Ritchlin, Christopher T, Elewaut, Dirk, Kanik, Keith S, Hendrikx, Thijs, Berstein, Gabriel, Hodge, Jennifer, Telliez, Jean-Baptiste
Publicado 2019

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

por Gladman, Dafna D., Orbai, Ana-Maria, Gomez-Reino, Juan, Chang-Douglass, Stacey, Leoncini, Emanuele, Burton, Hannah E., Kanik, Keith S., Romero, Ana Belen, Cappelleri, Joseph C., Hsu, Ming-Ann
Publicado 2020

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

por Deodhar, Atul, Sliwinska-Stanczyk, Paula, Xu, Huji, Baraliakos, Xenofon, Gensler, Lianne S, Fleishaker, Dona, Wang, Lisy, Wu, Joseph, Menon, Sujatha, Wang, Cunshan, Dina, Oluwaseyi, Fallon, Lara, Kanik, Keith S, van der Heijde, Désirée
Publicado 2021

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

por Burmester, Gerd R., Curtis, Jeffrey R., Yun, Huifeng, FitzGerald, Oliver, Winthrop, Kevin L., Azevedo, Valderilio F., Rigby, William F. C., Kanik, Keith S., Wang, Cunshan, Biswas, Pinaki, Jones, Thomas, Palmetto, Niki, Hendrikx, Thijs, Menon, Sujatha, Rojo, Ricardo
Publicado 2020

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

por Nash, Peter, Coates, Laura C., Kivitz, Alan J., Mease, Philip J., Gladman, Dafna D., Covarrubias-Cobos, José A., FitzGerald, Oliver, Fleishaker, Dona, Wang, Cunshan, Wu, Joseph, Hsu, Ming-Ann, Menon, Sujatha, Fallon, Lara, Romero, Ana Belén, Kanik, Keith S.
Publicado 2020

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

por Leng, Xiaomei, Lin, Wei, Liu, Shixue, Kanik, Keith, Wang, Cunshan, Wan, Weiguo, Jiang, Zhenyu, Liu, Yi, Liu, Shengyun, Zhang, Zhuoli, Zhang, Zhiyi, Xu, Jian, Tan, Wenfeng, Hu, Jiankang, Li, Jingyang, Liu, Ju, Gunay, Levent M., Dina, Oluwaseyi, Kinch, Cassandra, Zeng, Xiaofeng
Publicado 2023

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-worl...

por Mease, Philip, Charles-Schoeman, Christina, Cohen, Stanley, Fallon, Lara, Woolcott, John, Yun, Huifeng, Kremer, Joel, Greenberg, Jeffrey, Malley, Wendi, Onofrei, Alina, Kanik, Keith S, Graham, Daniela, Wang, Cunshan, Connell, Carol, Valdez, Hernan, Hauben, Manfred, Hung, Eric, Madsen, Ann, Jones, Thomas V, Curtis, Jeffrey R
Publicado 2020